How do you pay?

How to pay the least

Ask for the cash price

Breyanzi

Breyanzi is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

What to do

  1. Ask your pharmacy for Breyanzi’s cash price, and one or two other pharmacies too.

Compare every option

Brand name

Breyanzi, the original

Cash priceAsk the pharmacy
Ways to save on Breyanzi

The maker’s card

Cell Therapy 360 Copay Assistance Program

Savings card from Bristol Myers Squibb

Breyanzi’s maker has a savings program. Its page doesn’t list a dollar amount.

Sign up on breyanzi.com 

Or call 1-888-805-4555.

From the maker’s site, checked November 17, 2026. Check the maker’s page for who can use it.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

Breyanzi is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Not soldAsk the pharmacy

What it’s used for

What the FDA label says

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

  • adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
    • refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
    • refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
    • relapsed or refractory disease after 2 or more lines of systemic therapy.

Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.

  • adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
  • adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy.
  • adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
  • adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least 2 prior lines of systemic therapy.

Source: the FDA label for Breyanzi (Juno Therapeutics, Inc.), February 20, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.